134 related articles for article (PubMed ID: 10325520)
1. Prostate Cancer Prevention Trial (PCPT) update.
Coltman CA; Thompson IM; Feigl P
Eur Urol; 1999; 35(5-6):544-7. PubMed ID: 10325520
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification.
Ankerst DP; Thompson IM
Arch Ital Urol Androl; 2006 Dec; 78(4):125-9. PubMed ID: 17269614
[TBL] [Abstract][Full Text] [Related]
3. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
[TBL] [Abstract][Full Text] [Related]
5. [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].
Schmitz-Dräger BJ; Fischer C; Bismarck E; Dörsam HJ; Lümmen G
Urologe A; 2007 Oct; 46(10):1364, 1366-8, 1370. PubMed ID: 17874228
[TBL] [Abstract][Full Text] [Related]
6. The influence of finasteride on the development of prostate cancer.
Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
[TBL] [Abstract][Full Text] [Related]
7. [Practical follow-up of a patient treated with finasteride in screening for prostate cancer].
Villers A
Prog Urol; 2008 Apr; 18 Suppl 3():S58-62. PubMed ID: 18455086
[TBL] [Abstract][Full Text] [Related]
8. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
[TBL] [Abstract][Full Text] [Related]
9. Five-alpha-reductase Inhibitors for prostate cancer prevention.
Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
Cochrane Database Syst Rev; 2008 Apr; (2):CD007091. PubMed ID: 18425978
[TBL] [Abstract][Full Text] [Related]
10. Design of the Prostate Cancer Prevention Trial (PCPT).
Feigl P; Blumenstein B; Thompson I; Crowley J; Wolf M; Kramer BS; Coltman CA; Brawley OW; Ford LG
Control Clin Trials; 1995 Jun; 16(3):150-63. PubMed ID: 7540965
[TBL] [Abstract][Full Text] [Related]
11. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.
Lucia MS; Darke AK; Goodman PJ; La Rosa FG; Parnes HL; Ford LG; Coltman CA; Thompson IM
Cancer Prev Res (Phila); 2008 Aug; 1(3):167-73. PubMed ID: 19138952
[TBL] [Abstract][Full Text] [Related]
12. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
[TBL] [Abstract][Full Text] [Related]
13. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
[TBL] [Abstract][Full Text] [Related]
14. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
[TBL] [Abstract][Full Text] [Related]
15. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.
Andriole GL; Guess HA; Epstein JI; Wise H; Kadmon D; Crawford ED; Hudson P; Jackson CL; Romas NA; Patterson L; Cook TJ; Waldstreicher J
Urology; 1998 Aug; 52(2):195-201; discussion 201-2. PubMed ID: 9697781
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of men on finasteride.
Gormley GJ
Semin Urol Oncol; 1996 Aug; 14(3):139-44. PubMed ID: 8865475
[TBL] [Abstract][Full Text] [Related]
17. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial.
D'Amico AV; Roehrborn CG
Lancet Oncol; 2007 Jan; 8(1):21-5. PubMed ID: 17196507
[TBL] [Abstract][Full Text] [Related]
18. [Screening of cancer of the prostate: study in a Spanish population].
Herrero Payo JA; Montes Díaz MJ; Páez Borda A; Sánchez Sánchez E; Moreno Valle JA; Berenguer Sánchez A
Arch Esp Urol; 1996; 49(6):595-606. PubMed ID: 8929102
[TBL] [Abstract][Full Text] [Related]
19. [The PCPT trial].
Hamdy FC; Rouprêt M
Prog Urol; 2008 Apr; 18 Suppl 3():S40-3. PubMed ID: 18455082
[TBL] [Abstract][Full Text] [Related]
20. Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer.
Stamatiou K; Alevizos A; Karanasiou V; Mariolis A; Mihas C; Papathanasiou M; Bovis K; Sofras F
Urol Int; 2007; 78(4):313-7. PubMed ID: 17495488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
